What the research found

SS-31 (now branded FORZINITY) is a four-amino-acid peptide designed to stabilize cardiolipin, a structural lipid that holds the inner mitochondrial membrane architecture together. The peptide concentrates inside mitochondria at very high levels and binds cardiolipin in a way that maintains the tight membrane folds and protein assemblies needed for efficient ATP production. When researchers mapped what the peptide physically contacts inside working mitochondria, all its binding partners turned out to be cardiolipin-binding proteins clustered around energy-production machinery—suggesting the mechanism is genuinely specific to mitochondrial structure rather than a general cellular stimulant.

In September 2025, the FDA approved FORZINITY on a provisional basis for Barth syndrome, a rare genetic disease affecting roughly 150 people in the United States. The approval was anchored by a trial of 12 patients, though notably that trial did not meet either of its two primary endpoints. The drug is given as a 40 mg subcutaneous injection once daily. Approval came with a condition: the manufacturer must run a confirmatory trial (which enrolled its first patient in July 2026) to establish whether the drug actually delivers clinical benefit.

A critical detail: there have been no human trials of SS-31 for anti-aging, and when the same molecule was tested at larger scale for a broader mitochondrial-energy problem, it showed no detectable effect (p=0.69). The peptide appears to work as a repair mechanism in aged or damaged mitochondria, not as a performance enhancer in healthy tissue.

Why it matters for you

If you've been buying SS-31 as a longevity compound, the FDA approval does not validate that use. The agency approved a drug for a specific genetic disease in children and adults, not a biohacking tool. The mechanism—stabilizing cardiolipin and mitochondrial membrane structure—is real and well-characterized at the cellular level, but human evidence for anti-aging benefit doesn't exist yet.

The peptide's lack of effect in young, healthy mitochondria is particularly relevant if you're tracking biomarkers or measuring performance improvements. SS-31 is not a metabolic throttle. If your mitochondria are functioning normally, this peptide won't make them function better. It may have a role in recovery from sustained metabolic stress, intense training-induced oxidative damage, or age-related decline in mitochondrial function, but those applications remain speculative.

The provisional approval and failed primary endpoints also matter contextually. This is not a fully validated therapeutic yet. If you're considering use based on the September 2025 approval, you're essentially enrolling in the same confirmatory trial that's ongoing—except without the clinical monitoring, standardized dosing validation, or safety oversight that trial participants receive.

Caveats

  • Preclinical foundation: The mechanism is established through cell and tissue work, not human studies. The leap from cardiolipin binding to actual human benefit is unproven.
  • Trial failed primary endpoints: The 12-patient trial that anchored FDA approval did not meet its stated efficacy goals, yet approval proceeded anyway (on a provisional pathway).
  • Zero anti-aging human data: No human trial has tested SS-31 for aging or longevity—the entire "anti-aging peptide" framing rests on cellular and animal work.
  • No effect in healthy tissue: The peptide shows little activity in normally functioning mitochondria, limiting its utility as a performance or optimization tool.
  • Conditional and provisional: FDA approval is not final; it depends on results from an ongoing confirmatory trial.
  • Gray-market dosing uncertainty: Research-chemical vendors are selling SS-31 at undefined purity and potency, likely at doses not based on human pharmacology.